1 hour ago
10
Key Highlights
- ARK Invest purchased 233,482 shares of Rocket Lab valued at approximately $16.4 million on October 1.
- The investment firm offloaded 20,805 Palantir shares valued at around $4 million during the same trading session.
- Additional purchases included BWX Technologies, Intellia Therapeutics, and Veracyte stocks.
- ARK reduced holdings in Alphabet and liquidated a minor Zillow stake.
- Analysts assign Rocket Lab a Strong Buy consensus with 56% potential upside, compared to Palantir’s Moderate Buy rating with 6% upside potential.
Cathie Wood’s ARK Invest executed multiple strategic stock transactions on Thursday, October 1, according to the firm’s publicly disclosed trading activity. The moves included significant acquisitions and strategic exits across several positions.
The investment management company acquired 233,482 shares of Rocket Lab distributed across three different ARK funds. This combined purchase represented an investment totaling approximately $16.4 million.
Simultaneously, ARK divested 20,805 shares of Palantir Technologies. This divestment generated proceeds valued at nearly $4 million.
Year-to-date performance shows Rocket Lab shares climbing roughly 1%. Meanwhile, Palantir has posted gains of approximately 7% over the identical timeframe.
Rocket Lab Secures Major Launch Agreement and Expands Revenue
Rocket Lab achieved a milestone by securing its most substantial commercial contract for the Electron launch vehicle. The agreement encompasses 20 additional launches for Japanese firm Synspective.
This expansion brings Synspective’s total mission count with Rocket Lab to 47. The robust pipeline provides enhanced revenue visibility for the aerospace company.
Rocket Lab delivered second-quarter revenue of $234 million, representing a 62% year-over-year increase compared to the prior-year period.
Development continues on the company’s Neutron launch vehicle. Additionally, Rocket Lab is pursuing the proposed acquisition of satellite communications provider Iridium Communications.
Wall Street sentiment toward Rocket Lab remains predominantly bullish. Among 16 covering analysts, 14 maintain Buy ratings while 2 assign Hold recommendations.
The consensus price target stands at $110.07 for Rocket Lab shares, implying 56% upside potential from present trading levels.
Palantir Demonstrates Robust Commercial Revenue Acceleration
Palantir posted second-quarter revenue of $1.94 billion, marking a 93% surge versus the year-ago quarter. U.S. commercial revenue specifically jumped 149% to $764 million.
The data analytics platform provider executed 220 contracts valued at $1 million or higher throughout the quarter, demonstrating sustained enterprise demand for its software solutions.
Strategic partnerships have expanded Palantir’s ecosystem, including collaborative agreements with Nebius, PwC, and Armada.
Analyst sentiment on Palantir remains favorable, albeit with less enthusiasm than Rocket Lab receives. Out of 22 analysts tracking the stock, 16 recommend Buy, 4 suggest Hold, and 2 advise Sell.
Palantir’s consensus price target registers at $201.74, representing approximately 6% appreciation from current valuation levels.
ARK’s trading activity extended beyond these two positions. The firm acquired shares in BWX Technologies, which manufactures nuclear energy components, totaling roughly $13.6 million in value.
The investment manager also expanded its holdings in Intellia Therapeutics, a biotechnology company focused on gene editing. This transaction was valued at approximately $5 million.
ARK added shares of Veracyte, a company specializing in genomic diagnostic testing, with purchases exceeding $7.3 million.
Regarding divestments, ARK decreased its Alphabet position by selling 101 shares. The firm also eliminated a minor Zillow position valued at roughly $20,000.
These transactions form part of ARK’s standard practice of publishing daily trade disclosures across all its actively managed exchange-traded funds.
The post Cathie Wood’s Fund Sells Palantir (PLTR) Shares, Boosts Rocket Lab (RKLB) Holdings by $16M appeared first on Blockonomi.
English (US) ·